## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.7% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($51.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. WATCH: Trump announces 9 pharmaceutical companies will lower drug prices**
- Source: PBS | 20251219T220751 | Somewhat-Bullish | Relevance: 100%
- President Donald Trump announced that nine major pharmaceutical companies have agreed to lower the cost of their prescription drugs in the U.S., including matching prices charged in other developed countries. This deal extends to new drugs with "most-favored-nation" pricing for all markets and includes commitments to sell drugs on the TrumpRx platform set to launch in January. Additionally, some companies will donate significant supplies of active pharmaceutical ingredients and specific vital medications like Eliquis to national reserves and Medicaid.

**2. Accenture helps Bristol Myers Squibb to launch AI-based medical content hub Mosaic**
- Source: Times of India | 20251217T210857 | Bullish | Relevance: 100%
- Bristol Myers Squibb and Accenture have launched Mosaic, an AI-powered medical content hub in Mumbai, India. This hub utilizes generative AI to create patient-centric content and aims to enhance communication between the biopharmaceutical company and healthcare professionals. The initiative is part of Bristol Myers Squibb's $130 million investment in AI projects and leverages India's tech talent to accelerate commercialization efforts and improve healthcare content delivery globally.

**3. Is Bristol Myers (BMY) Undervalued After Its Recent Share Price Rebound?**
- Source: Simply Wall Street | 20251217T034657 | Neutral | Relevance: 100%
- Bristol-Myers Squibb (BMY) has seen a recent rebound in its share price, rising approximately 16% over the last month, despite a previous dip in revenue. While a "narrative fair value" suggests the stock is slightly overvalued at $54.23, Simply Wall St's DCF model indicates it might be significantly undervalued by about 54%, implying a potential intrinsic value of $117.66. This divergence highlights differing perspectives on the company's true value, with factors like patent cliffs and pricing reforms posing potential risks.

**4. Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies**
- Source: PR Newswire | 20251217T000558 | Bullish | Relevance: 100%
- Harbour BioMed has announced a multi-year global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies. This partnership leverages Harbour BioMed's proprietary Harbour Mice® technology platform and could lead to payments totaling $90 million, plus potential development and commercial milestones of up to $1.035 billion, along with tiered royalties. The collaboration aims to accelerate programs and bring transformative therapies to patients worldwide.

**5. Bristol Myers Squibb to provide Eliquis free to Medicaid starting 2026**
- Source: Investing.com | 20251219T210924 | Bullish | Relevance: 100%
- Bristol Myers Squibb announced an agreement to provide its blood thinner Eliquis at no cost to the Medicaid program starting January 1, 2026, and will also donate over seven tons of Eliquis active pharmaceutical ingredient to the U.S. Strategic Active Ingredient Reserve. In exchange for this, BMS will receive tariff relief and will not be subject to future pricing mandates. In other news, the company is expanding its clinical trials for an Alzheimer’s drug and acquiring Orbital Therapeutics for its CAR T-cell therapy platform.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.3B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.0 |
| Current P/E | 8.3 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 7.3% to 2.7% (-4.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.3pp (needs >3.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.71% (CS: 89) | Neutral |
| RSI_14 | 69.7 | Neutral |
| MACD Histogram | 0.19 | Bullish |
| vs SMA20 | 1.062x | Above |
| vs SMA50 | 1.138x | Above |
| vs SMA200 | 1.111x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $54.20
- **Stop Loss:** $51.56 (4.9% risk)
- **Target:** $56.84 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 454
- **Position Value:** $24,606.80
- **Portfolio %:** 24.61%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*